Posts tagged “UNC-CH”
MCNC, the non-profit operator of the North Carolina Research and Education Network (NCREN), says that as it starts a new fiscal year with growing revenue and employee base it is ready to bring broadband connectivity levels in the state to all-time highs.
The North Carolina Biotechnology Center awarded 36 loans and grants totaling nearly $2.5 million to universities and bioscience companies during the fourth quarter of its 2015-2016 fiscal year ending June 30.
What is the next step in virtual reality technology? It's "mixed reality," the merger of virtual reality with the real world, according to R. Benjamin Knapp, PhD, director of the Institute for Creativity, Arts, and Technology (ICAT) at Virginia Tech during the "How Close Can We Get to a Holodeck event at Moog fest Friday morning.
The medal has been delivered - Dr. Joseph DeSimone is one happy man. The inventor, professor, entrepreneur received the National Medal of Technology and Innovation from President Obama on Thursday in a White House ceremony, and his response when asked beforehand if he was excited he replied: "Are you kidding me? THRILLED!" By the way, he also had some ideas on innovation to share with the President. Later, he tweets: "Wow. Humbling."
In a wrapup of technology and life science news being reported by Triangle media outlets: TransEnterix cuts jobs after FDA rejects robot; G1 Therapeutics adds to a big fundraiser; and a look at the joint UNC-NCSU biomedical engineering effort.
A team of UNC seniors wins the annual startup pitch competition at UNC-Chapel Hill and $10,000 with their Unisource app. ExitEvent's Edgar Walker reports.
Hatteras Ventures, a $350 million venture capital firm in Durham, says it will invest up to $10 million in startups linked to UNC-Chapel Hill. As part of the agreement, Hatteras will manage UNC's Carolina Research Ventures investment fund.
Boosted by a $250,000 federal grant, four Triangle Universities are forming the Triangle Venture Alliance which plans to work with alumni in funding startups. The alliance is the second major boost to emerging ventures in the Triangle in two days, NCSU having announced a new $1M fund and accelerator as well on Tuesday.
Dr. Terry Magnuson, a professor and geneticist researcher, will become the new vice chancellor for research at UNC-Chapel Hill on July 1. He will replace Dr. Barbara Entwisle.
GlaxoSmithKline is boosting its own efforts to fight AIDS by closing on a deal to buy the HIV drug pipeline of Bristol-Myers Squibb . The transaction is worth as much as $1.46 billion. In May, GSK said it would invest $20 million in a deal with UNC-Chapel Hill to develop an AIDS cure.
Answered prayers? Recently blessed for its work by the Pope, Bamboo Therapeutics, a recently launched life sciences venture focusing on gene therapy to treat deadly childhood neurological disorders, has raised nearly $50 million from investors. CureDuchenne Ventures LLC, a venture philanthropy organization, is among the backers.
Britain's decision to allow researchers to edit the genes of human embryos -- not to create babies but to start unraveling the earliest stages of development -- is raising new questions about the ethics of this hot new technology.
WalletHub published a report this week that says Raleigh ranks 14th among the nation's top 100 metro areas for STEM-related jobs. In a Q&A, WalletHub talked with Jeff Sackaroff, associated director of career services at UNC-Chapel Hill, about how areas can improve the STEM job environment and also attract more minorities as well as women.
Biomedical engineering researchers have developed a technique for creating microscopic "depots" for trapping drugs inside cancer tumors. In an animal model, these drug depots were 10 times more effective at shrinking tumors than the use of the same drugs without the depots.
Terra Dotta, which means "learned world," has been around since 2001 and has attracted more than 450 clients around the world for its software designed to help universities manage student data. On Monday, the company disclosed its growing appeal to investors, raising $6 million.
GlaxoSmithKline is boosting its own efforts to fight AIDS by agreeing to buy the HIV drug pipeline of Bristol-Myers Squibb in a deal valued at as much as $1.46 billion. In May, GSK said it would invest $20 million in a deal with UNC-Chapel Hill to develop an AIDS cure.